Skip to main content
SpringerLink
Log in

Selegiline as immunostimulant — a novel mechanism of action?

  • Conference paper
MAO — The Mother of all Amine Oxidases

Part of the book series: Journal of Neural Transmission. Supplement ((NEURAL SUPPL,volume 52))

Summary

In clinical studies the MAO-B inhibitor selegiline appears to slow the progression of neurological deficits in Parkinson’s disease (PD) and the cognitive decline in Alzheimer’s disease (AD). The mechanisms of action remain unclear. Several lines of evidence indicate an immune-mediated pathophysiology of PD and AD. According to animal trials, selegiline increases the survival rate of immune suppressed mice. Stimulation of the immune response to bacterial or viral infection or in chronic inflammatory processes is managed by an increased synthesis of the cytokines interleukin-lß (IL-1ß) and subsequent interleukin-6 (IL-6). Outcome of viral or bacterial infections in the brain highly correlates with levels of the cytotoxic cytokine tumor-necrosis-factor-alpha (TNF). The aim of our study was to characterize the influence of selegiline on the biosynthesis of IL-1ß, IL-6 and TNF in human peripheral blood mononuculear cells (PBMC) from healthy blood donors. After isolation and washing PBMC were cultured without and with selegiline in three different concentrations (0.01 μmol/l, 0.001 μmol/l, 0.0001 μmol/l) in a humidified atmosphere (7% CO2). Then cultures were centrifuged and supernatants were collected for IL-1ß, IL-6 and TNF ELISAassays. Treatment of cultured PBMC with various concentrations induced an increased synthesis of IL-lß (ANOVA F = 9.703, p = 0.0007), IL-6 (ANOVA F = 20.648, p = 0.0001) and a reduced production of TNF (ANOVA F = 3.770, p = 0.040). These results indicate, that the influence of selegiline on the cytokine biosynthesis may also contribute to its putative neuroprotective properties.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bartfai T, Schultzberg M (1993) Cytokines in neuronal cell types. Neurochem Int 22: 435–444

    Article  PubMed  CAS  Google Scholar 

  • Bauer J, Strauss S, Schreiter Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 285: 111–114

    Article  PubMed  CAS  Google Scholar 

  • Blum-Degen D, Müller Th, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1-beta and interleukin 6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202: 17–20

    Article  PubMed  CAS  Google Scholar 

  • Boka G, Anglade P, Wallach D, Javoy Agid F, Agid Y, Hirsch EC (1994) Immunocy-tochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172: 151–154

    Article  PubMed  CAS  Google Scholar 

  • Brosnan CF, Selmaj K, Raine CS (1988) Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuro-immunol 18: 87–94

    CAS  Google Scholar 

  • Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E (1991) Cerebrospinal fluid interleukin-1ß (IL-1ß) in Alzheimer’s disease and neurological disorders. Meth Find Exp Clin Pharmacol 13: 455–458

    CAS  Google Scholar 

  • Calne DB (1995) Selegiline in Parkinson’s disease. BMJ 311: 1583–1584

    Article  PubMed  CAS  Google Scholar 

  • Freisleben HJ, Lehr F, Fuchs J (1994) Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm [Suppl] 41: 231–236

    CAS  Google Scholar 

  • Gatti S, Bartfai T (1993) Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: comparison with interleukin-1 family and interleukin-6. Brain Res 624: 291–294

    Article  PubMed  CAS  Google Scholar 

  • Gabellec MM, Griffais R, Fillion G, Haour F (1995) Expression of interleukin-1α, interleukin-1ß and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Mol Brain Res 31: 122–130

    Article  PubMed  CAS  Google Scholar 

  • Gerlach M, Riederer P, Youdim MB (1995) Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochem Pharmacol 50: 1–16

    Article  PubMed  CAS  Google Scholar 

  • Glavin GB, Dugani AM, Pinsky C (1986) L-deprenyl attenuates stress ulcer formation in rats. Neurosci Lett 70: 379–381

    Article  PubMed  CAS  Google Scholar 

  • Gottschall PE, Komaki G, Arimura A (1991) Interleukin-1ß activation of the central nervous system. In: Rothwell N, Dantzer R (eds) Interleukin in the brain. Pergamon Press, Oxford, pp 27–49

    Google Scholar 

  • Goujon E, Parnet P, Laye S, Combe C, Dantzer R (1996) Adrenalectomy enhances proinflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Mol Brain Res 36: 53–62

    Article  PubMed  CAS  Google Scholar 

  • Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611–7615

    Article  PubMed  CAS  Google Scholar 

  • Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40: 445–452

    Article  PubMed  CAS  Google Scholar 

  • Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607–612

    Article  PubMed  CAS  Google Scholar 

  • Imamura K, Suzumura A, Hayashi F, Marunouchi T (1993) Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87: 281–285

    Article  PubMed  CAS  Google Scholar 

  • Imura H, Fukata J, Mori T (1991) Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol 35: 107–115

    Article  CAS  Google Scholar 

  • Inglot AD, Zielinska Jenczylik J, Piasecki E, Syper L, Mlochowski J (1990) Organoselenides as potential immunostimulants and inducers of interferon gamma and other cytokines in human peripheral blood leukocytes. Experientia 46: 308–311

    Article  PubMed  CAS  Google Scholar 

  • Knoll J (1995) Rationale for (-)deprenyl (selegiline) medication in Parkinson’s disease and in prevention of age-related nigral changes. Biomed Pharmacother 49: 187–195

    Article  PubMed  CAS  Google Scholar 

  • Kuhn W, Müller Th (1995) Neuroimmune mechanisms in Parkinson’s disease. J Neural Transm [Suppl] 46: 217–228

    Google Scholar 

  • Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659–2667

    PubMed  CAS  Google Scholar 

  • McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21: 195–218

    Article  PubMed  CAS  Google Scholar 

  • Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994a) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147–150

    Article  PubMed  CAS  Google Scholar 

  • Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994b) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208–210

    Article  PubMed  CAS  Google Scholar 

  • Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T (1995) Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson’s disease. J Neural Transm [Park Dis Dement Sect] 9: 87–92

    Article  CAS  Google Scholar 

  • Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS (1990) Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 87: 782–785

    Article  PubMed  CAS  Google Scholar 

  • Selmaj K, Raine CS (1988a) Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue. Ann NY Acad Sci 540: 568–570

    Article  PubMed  CAS  Google Scholar 

  • Selmaj K, Raine CS (1988b) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339–346

    Article  PubMed  CAS  Google Scholar 

  • Selmaj K, Bradbury K, Chapman J (1988a) Multiple sclerosis: effects of activated T-lymphocyte-derived products on organ cultures of nervous tissue. J Neuroimmunol 18: 255–268

    Article  PubMed  CAS  Google Scholar 

  • Selmaj K, Nowak Z, Tchorzewski H (1988b) Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients. J Neurol Sci 85: 67–76

    Article  PubMed  CAS  Google Scholar 

  • Selmaj K, Papierz W, Glabinski A, Kohno T (1995) Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56: 135–141

    Article  PubMed  CAS  Google Scholar 

  • Stoll S, Hafner U, Pohl O, Müller WE (1994) Age-related memory decline and longevity under treatment with selegiline. Life Sci 55: 2155–2163

    Article  PubMed  CAS  Google Scholar 

  • Strijbos PJ, Rothwell NJ (1995) Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J Neurosci 15: 3468–3474

    PubMed  CAS  Google Scholar 

  • Tatton WG, Ansari K, Ju W, Salo PT, Yu PH (1995) Selegiline induces “trophic-like” rescue of dying neurons without MAO inhibition. Adv Exp Med Biol 363: 15–16

    Article  PubMed  CAS  Google Scholar 

  • Thyagarajan S, Meites J, Quadri SK (1995) Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136: 1103–1110

    Article  PubMed  CAS  Google Scholar 

  • Wollmann EE, Kopmels B, Bakalian A, Delhaye-Bouchard N, Fradelizi D, Mariani J (1992) Cytokines and neuronal degeneration. In: Rothwell N, Dantzer R (eds) Interleukin in the brain. Pergamon Press, Oxford, pp 187–203

    Google Scholar 

  • Woodroofe MN (1995) Cytokine production in the central nervous system. Neurology 45: S6–S10

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi M, Matsuzaki N, Hirota K, Miyake A, Tanizawa O (1990) Interleukin 6 possibly induced by interleukin 1 beta in the pituitary gland stimulates the release of gonadotropins and prolactin. Acta Endocrinol Copenh 122: 201–205

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, St. Josef-Hospital, University of Bochum, Gudrunstrasse 56, D-44791, Bochum, Germany

    Th. Müller (M.D.), Th. Müller (M.D.), W. Kuhn, R. Krüger & H. Przuntek

Authors
  1. Th. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Przuntek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, The Bruce Rappaport Faculty of Medicine, Technion — Israel Institute of Technology, Haifa, Israel

    J. P. M. Finberg  & M. B. H. Youdim  & 

  2. Clinical Neurochemistry, Department of Psychiatry, University of Würzburg, Federal Republic of Germany

    P. Riederer

  3. Biochemistry Department, Trinity College, Dublin, Ireland

    K. F. Tipton

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Wien

About this paper

Cite this paper

Müller, T., Kuhn, W., Krüger, R., Przuntek, H. (1998). Selegiline as immunostimulant — a novel mechanism of action?. In: Finberg, J.P.M., Youdim, M.B.H., Riederer, P., Tipton, K.F. (eds) MAO — The Mother of all Amine Oxidases. Journal of Neural Transmission. Supplement, vol 52. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6499-0_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6499-0_33

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83037-6

  • Online ISBN: 978-3-7091-6499-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation